Comparability and biosimilarity: considerations for the healthcare provider
Authors:
- 1 June 2012
- journal article
- review article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 28 (6) , 1053-1058
Abstract
Healthcare providers use recombinant biologics such as monoclonal antibodies to treat a variety of serious illnesses. Manufacturing of approved biotechnology products is complex, and the quality of the resulting biologic is dependent on careful control of process inputs and operating conditions. Biosimilars, which are similar but not identical to innovator biologics, are entering regulatory evaluation, approval, and marketing in regions with biosimilar approval pathways. This article describes the evaluation and potential impact of manufacturing process changes and biosimilar product development, and explores the similarities and distinctions between the two. Regulatory agencies generally require a comparability exercise following a manufacturing process change. This comparability is focused primarily on analytical characterization of the approved product before and after the manufacturing process change, with non-clinical and clinical confirmation required when determined necessary. When developing a biosimilar, the manufacturer does not have access to key information including the innovator manufacturer’s cell line, cell culture conditions, purification procedures, and fill and finish processes. Further, the biosimilar manufacturer does not have access to information about the innovator manufacturer’s product development history, including knowledge about the quality attributes of lots used in non-clinical and clinical development. We define the biosimilar manufacturer’s lack of information as the knowledge gap. As a result, a biosimilarity exercise to compare a biosimilar to an approved innovator biologic requires a rigorous evaluation to ensure the safety and efficacy of the biosimilar. Given the knowledge gap under which biosimilars are developed, data to establish biosimilarity should go beyond a simple comparability exercise.Keywords
This publication has 13 references indexed in Scilit:
- Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind studyClinical Nephrology, 2012
- Biosimilars 2.0mAbs, 2011
- Comparability assessments of process and product changes made during development of two different monoclonal antibodiesBiologicals, 2011
- Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodiesTrends in Biotechnology, 2010
- Summary of DIA Workshop: Comparability Challenges: Regulatory and Scientific Issues in the Assessment of BiopharmaceuticalsDrug Information Journal, 2010
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009
- Current Perspectives on Stability of Protein Drug Products during Formulation, Fill and Finish OperationsBiotechnology Progress, 2008
- EMEA Guidelines on Biosimilars and Their Clinical ImplicationsKidney and Blood Pressure Research, 2007
- Combined approach of NMR and chemometrics for screening peptones used in the cell culture medium for the production of a recombinant therapeutic proteinBiotechnology and Bioengineering, 2007
- Current and future considerations for the new classes of biologicalsAmerican Journal of Health-System Pharmacy, 2004